Steering Committee Members

The Steering Committee was formed at the beginning of the Guideline development process and was made up of researchers, end-users, and representatives from interested societies (e.g., RACGP). The committee is also made up of representatives from different Australian jurisdictions. The aim of the committee is to: provide direction and scope for the guidelines, recommend members of the working group, and to offer ongoing feedback throughout the project.

The Steering Committee met regularly during the Guideline development process via tele-conference. The Steering Committee also attended the dedicated Symposium for the Guidelines held at the University of Sydney, where they offered feedback on the preliminary recommendations from the Guidelines.

Member		Affiliation
Professor Paul Haber AM (Chair)*		Specialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, New South Wales Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District, New South Wales Edith Collins Centre (Translational Research in Alcohol Drugs and Toxicology), Sydney Local Health District, New South Wales
Professor Anthony Shakeshaft		National Drug and Alcohol Research Centre, Faculty of Medicine, University of New South Wales, New South Wales
Dr Chris Davis		Royal Australian College of General Practitioners Royal Australasian College of Physicians, Faculty of Addiction Medicine Advanced Trainee East Sydney Doctors, Darlinghurst, New South Wales
Professor Dan Lubman*		Turning Point, Eastern Health, Melbourne, Victoria Eastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria
Professor Jason Connor		National Centre for Youth Substance Use Research, Faculty of Health and Behavioural Sciences, The University of Queensland, Queensland School of Psychology, Faculty of Health and Behavioural Sciences, The University of Queensland, Queensland Alcohol and Drug Assessment Unit, Princess Alexandra Hospital, Brisbane, Queensland
Professor Kate Conigrave		Centre of Research Excellence in Indigenous Health and Alcohol Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District, New South Wales Specialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, New South Wales Edith Collins Centre (Translational Research in Alcohol Drugs and Toxicology), Sydney Local Health District, New South Wales
Associate Professor Kirsten Morley		Specialty of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, New South Wales Edith Collins Centre (Translational Research in Alcohol Drugs and Toxicology), Sydney Local Health District, New South Wales
Dr Michael Aufgang		General Practitioner, Melbourne, Victoria
Professor Steve Allsop		National Drug Research Institute, Curtin University, Western Australia
Associate Professor Robert Ali		Discipline of Pharmacology, School of Medicine, The University of Adelaide, South Australia

*Conflict of interest declared

Steering Committee Conflicts of Interest

Member	Conflict	How conflict is managed
Paul Haber AM	Funded by the Lambert Cannabis Initiative at the University of Sydney to undertake clinical trials of cannabinoid treatment for alcohol withdrawal syndrome. Has served on industry advisory boards for Indivior, AbbVie and Gilead and has been an investigator on clinical trials supported by Camurus. He has also served on an International Advisory Board for Lundbeck in relation to nalmefene (2013-2015) and Australia (2014).	Cannabis is not discussed in these Guidelines and Indivior, AbbVie and Gilead do not market products for treatment of alcohol problems. Nalmefene is discussed in the pharmacotherapies chapter and while the drug is TGA approved, it is not available in Australia. To manage this conflict, Paul did not review the section on Nalmefene.
Dan Lubman	Has received grant income form the ARC, NHMRC, Movember, beyondblue, VicHealth, Google, VGRF, NSW Health, the Victorian Department of Health and the Commonwealth Department of Health. Has also provided consultancy advice to Lundbeck and Indivior and has received travel support and speaker honoraria from Astra Zeneca, Janssen, Lundbeck, Shire, and Servier, though none of these organisations stand to benefit from the current project. DL has been an investigator on an untied education grant from Sequirus, unrelated to the current work.	To manage any potential conflicts, Dan did not review the pharmacotherapy section or other sections related to these conflicts.

About the Guidelines for the Treatment of Alcohol Problems

Working Group Members

Acknowledgements

Navigating the Guidelines